The Expanding Sickle Cell Anemia Testing and Screening Market is driven by increasing government initiatives
The global sickle cell anemia testing and screening market overview is a rapidly evolving area focused on diagnosing sickle cell disease and carriers through various techniques including electrophoresis, HPLC analysis, and genetic testing. Sickle cell anemia is a hereditary blood disorder characterized by abnormal hemoglobin that can lead to life-threatening complications. There is currently no cure for the disease, but proper management through regular screening, medicines, hydration, and vaccination can help manage symptoms and reduce the risk of medical crises.
The global sickle cell anemia testing and screening market is estimated to be valued at USD 465.2 Mn in 2024 and is expected to reach USD 1,028.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 12% from 2024 to 2031.
Key Takeaways
Key players operating in the sickle cell anemia testing and screening market are Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agios Pharmaceuticals, Inc., Bluebird bio, Inc., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Global Blood Therapeutics, Inc., Edvotek Inc., Maternova Inc., Hemex Health, CRISPR Therapeutics, Anamol Laboratories Pvt. Ltd., Atlas Medical GmbH, and Calibre Scientific, Inc. They are focusing on new product launches, collaborations, and licensing agreements to strengthen the
The global sickle cell anemia testing and screening market overview is a rapidly evolving area focused on diagnosing sickle cell disease and carriers through various techniques including electrophoresis, HPLC analysis, and genetic testing. Sickle cell anemia is a hereditary blood disorder characterized by abnormal hemoglobin that can lead to life-threatening complications. There is currently no cure for the disease, but proper management through regular screening, medicines, hydration, and vaccination can help manage symptoms and reduce the risk of medical crises.
The global sickle cell anemia testing and screening market is estimated to be valued at USD 465.2 Mn in 2024 and is expected to reach USD 1,028.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 12% from 2024 to 2031.
Key Takeaways
Key players operating in the sickle cell anemia testing and screening market are Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agios Pharmaceuticals, Inc., Bluebird bio, Inc., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Global Blood Therapeutics, Inc., Edvotek Inc., Maternova Inc., Hemex Health, CRISPR Therapeutics, Anamol Laboratories Pvt. Ltd., Atlas Medical GmbH, and Calibre Scientific, Inc. They are focusing on new product launches, collaborations, and licensing agreements to strengthen the
5 days ago
